Chromosomal location: 11p15 Produced from sera of rabbits immunized with highly pure recombinant human soluble LYVE-1 produced in insect cells. The recombinant soluble LYVE-1consists of amino acid 24 (Ser) to 232 (Gly) and is fused to a C-terminal His-tag (6xHis). LYVE-1 has been identified as a major receptor for HA (extracellular matrix glycosaminoglycan hyaluronan) on the lymph vessel wall. The deduced amino acid sequence of LYVE-1 predicts a 322-residue type I integral membrane polypeptide 41% similar to the CD44 HA receptor with a 212-residue extracellular domain containing a single Link module the prototypic HA binding domain of the Link protein superfamily. Like CD44, the LYVE-1 molecule binds both soluble and immobilized HA. However, unlike CD44, the LYVE-1 molecule co-localizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels. Hence, LYVE-1 is the first lymph-specific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves.
LYVE1
Reactivity: Mouse
IHC, IF
Host: Rabbit
Polyclonal
unconjugated
Application Notes
Western Blot: Use 2-5 μg/mL
Restrictions
For Research Use only
Format
Lyophilized
Reconstitution
Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/mL.
Buffer
PBS
Handling Advice
Centrifuge vial prior to opening.
Storage
4 °C,-20 °C
Storage Comment
The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots.
Expiry Date
24 months
Matsusaki, Fujimoto, Shirakata, Hirakawa, Hashimoto, Akashi: "Development of full-thickness human skin equivalents with blood and lymph-like capillary networks by cell coating technology." in: Journal of biomedical materials research. Part A, (2015) (PubMed).
Roost, van Iperen, de Melo Bernardo, Mummery, Carlotti, de Koning, Chuva de Sousa Lopes: "Lymphangiogenesis and angiogenesis during human fetal pancreas development." in: Vascular cell, Vol. 6, pp. 22, (2015) (PubMed).
Rohringer, Holnthoner, Hackl, Weihs, Rünzler, Skalicky, Karbiener, Scheideler, Pröll, Gabriel, Schweighofer, Gröger, Spittler, Grillari, Redl: "Molecular and cellular effects of in vitro shockwave treatment on lymphatic endothelial cells." in: PLoS ONE, Vol. 9, Issue 12, pp. e114806, (2014) (PubMed).
Kawai, Kaidoh, Yokoyama, Ohhashi: "Pivotal roles of lymphatic endothelial cell layers in the permeability to hydrophilic substances through collecting lymph vessel walls: effects of inflammatory cytokines." in: Lymphatic research and biology, Vol. 12, Issue 3, pp. 124-35, (2014) (PubMed).
LYVE1, HAR, XLKD1, LYVE-1, CRSBP-1,LYVE-1 has been identified as a major receptor for HA (extracellular matrix glycosaminoglycan hyaluronan) on the lymph vessel wall. The deduced amino acid sequence of LYVE-1 predicts a 322-residue type I integral membrane polypeptide 41 % similar to the CD44 HA receptor with a 212-residue extracellular domain containing a single Link module the prototypic HA binding domain of the Link protein superfamily. Like CD44, the LYVE-1 Molecule binds both soluble and immobilized HA. However, unlike CD44, the LYVE-1 Molecule colocalizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels. Hence, LYVE-1 is the first lymph-specific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves.